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ABSTRACT 
Among the potential nonviral vectors for hunian gene therapy are DNA-liposome complexes. In a recent 
clinical study, this delivery system has been utilized. In this report, a novel cationic lipid, dimyristyloxypropyl-
3-dimethyl-hydroxyethyl a m m o n i u m ( D M R I E ) , has been substituted into the DNA-liposome complex with 
dioleoyl phosphatidylethanolamine ( D O P E ) , which both improves transfection efficiencies and allows in-
creased doses of D N A to be delivered in vivo. The safety and toxicity of this DNA-liposome complex has been 
evaluated in two species, mice and pigs. The efficacy of D M R I E / D O P E in inducing an antitumor response in 
mice after transfer ofa foreign M H C has been confirmed. N o abnormalities were detected after administration 
of up to 1,000-fold higher concentrations of D N A and lipid than could be tolerated in vivo previously. 
Examination ofserum biochemical enzymes, pathologic examination of tissue, and analysis of cardiac function 
in mice and pigs revealed no toxicities related to this treatment. This improved cationic lipid formulation is 
well-tolerated in vivo and could therefore allow higher dose administration and potentially greater efficiency of 
gene transfer for gene therapy. 
OVERVIEW SUMMARY INTRODUCTION 
A l t h o u g h several viral vectors have been widely applied 
to the treatment of human disease, the development of 
nonviral vectors is still in their infancy. In this report, a 
novel cationic lipid, DMRIE/DOPE, has been incorporated 
into the DNA-liposome formulation that improves transfec-
tion efficiencies and allows up to 1,000-fold higher concen-
trations of D N A to be administered in vivo. In this paper, 
the safety and toxicity of this formulation is described in two 
species, mice and pigs, suggesting that it may prove useful 
for human gene therapy. 
A L T H O U G H SEVERAL VIRAL DELIVERY SYSTEMS are available 
for human gene therapy, nonviral vectors are not as well 
utilized for gene transfer in vivo. W e have previously employed 
a nonviral vector in a human gene therapy protocol in an at-
tempt to stimulate tumor immunity by expression of a foreign 
histocomparibility antigen in patients with melanoma (G.J. 
Nabel era/., 1992a,b, 1993). Although several features of such 
nonviral vectors are attractive for direct gene transfer in vivo, a 
limitation of this system is the relative efficiency of gene trans-
fer. Although the ability to deliver recombinant genes with 
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DNA-liposome complexes and to modify biologic effects in 
vivo has been established (E.G. Nabel et al., 1992b, 1993a,b; 
Plautz et al., 1993), the ability to transduce larger numbers of 
cells could greatly expand its utility. 
There are several potential advantages of DNA-liposome 
complexes as a nonviral delivery system. Because the D N A is 
not directly derived from a replication competent virus, its 
expression is limited. It is unlikely to integrate or propagate in 
animal cells, thus minimizing concems related to public health 
and vector safety. In addition, cationic lipids have been well-
tolerated in vivo (E.G. Nabel et al., 1992a; Stewart et al., 
1992). Based on a variety of animal models (E.G. Nabel et al., 
1992a,b, 1993a,b; Stewart et al., 1992) and clinical studies 
(G.J. Nabel et al., 1992a, 1993) in progress, applicarions of 
this technology are likely to expand in the future. Finally, the 
ability to deliver recombinant genes using catheter-based deliv-
ery has further allowed for site-specific gene expression in vivo. 
Despite the advantages of this technique, some limitarions of 
the present technology remain. Among them has been the rela-
tively low concentration of DNA-liposome complexes that are 
employed. In previous studies, higher absolute concentrations 
of DNA-liposome complexes led to aggregation and toxicity 
following intravenous injection in mice in vivo (Stewart et al., 
1992). A new formulation (Feigner et al., 1993) is character-
ized in this report. This DNA-liposome formulation displays a 
modestly higher transfection efficiency in vitro. More impor-
tantly, it does not show toxicity at higher absolute concentra-
tions of D N A and lipid. In this report, we characterize the in 
vivo toxicities of this formulation in mice and pigs. W e find 
minimal toxicity at lipid and D N A concentrations up to 1000-
fold higher than those used previously. Based on these results, 
this DNA-liposome formulation may be an appropriate deliv-
ery vehicle for gene transfer in humans. 
MATERIALS AND METHODS 
Plasmids and transfections 
A plasmid containing the HLA-B7 gene (G.J. Nabel et al., 
1992a, 1993) under the control of the Rous sarcoma virus long 
terminal repeat (RSV-LTR) was used for transfection of differ-
ent primary and transformed cell lines and for in vivo toxicity 
analysis. This plasmid was approved for use in our previous 
human clinical protocol (G.J. Nabel etal., 1992a, 1993). Cells 
were transfected with dimethylaminoethane-carbamoyl choles-
terol (DC-Chol)/dioleoyl phosphatidylethanolamine (DOPE) in 
an optimal concentration (15 nmol DC-Chol/DOPE; I p,g D N A 
in 0.7 ml) as previously described (Gao and Huang, I99I; 
Stewart et al., 1992). The newer DNA-liposome formulation 
was prepared by incubation of D N A (5 p,g) and dimyristyloxy-
propyl-3-dimethyl-hydroxyethyl ammonium (DMRIE)/DOPE 
(15 nmol) in a final volume of 1 ml in lactated Ringer's solution 
for in vitro transfections. 
Animal studies 
Adult female mice (strain BALB/c) and domestic pigs were 
used for all in vivo experiments. Experiments in mice were 
performed to evaluate escalating doses of D N A and liposomes 
injected intravenously. Intravenous injections were carried out 
via the tail vein using a 21-gauge needle. In mice, for intrave-
nous injections, D N A (0.5-50 p,g) and DMRIE/DOPE (1.5-
150 nmol) were mixed in a final volume of 0.1 ml immediately 
prior to injection. Blood was collected from the tail vein before 
intravenous injection ofthe DNA-liposomes and 10 days later. 
At about 2 weeks following injection, liver, kidney, lung, 
heart, and brain were removed for histologic analysis and ex-
tracted for polymerase chain reaction (PCR) D N A amplification 
using primers and conditions described previously (G.J. Nabel 
et al., 1993) in one group of mice (n = 5). In a second group, 
injections were repeated at 2-week intervals for a total of three 
times. Blood was collected before the first injections and 6 
weeks later, at which time organs were removed and analyzed 
by histology and PCR. 
Additional toxicity studies were performed in 12 pigs to 
evaluate the local and systemic effects of three doses of D N A 
and liposomes when delivered by a catheter to a local peripheral 
artery segment. Intra-arterial gene transfer was performed using 
a double balloon catheter (USCI, Bard, Inc., Billerica, M A ) 
with methods previously described (Nabel et al., 1990). In 
these experiments, the plasmid containing the HLA-B7 gene 
was mixed with DMRIE/DOPE in three concentrations: 
HLA-B7 D N A 0.5 p,g and DMRIE/DOPE 1.5 nmol (2 pigs); 
HLA-B7 D N A 5 p,g and DMRIE/DOPE 15 nmol (4 pigs); 
and HLA-B7 D N A 50 p,g and DMRIE/DOPE 150 nmol 
(6 pigs). The animals were sacrificed at 17-21 days. The fol-
lowing evaluations were performed. Tissue analysis for PCR 
and histology were done 17-21 days following gene transfer to 
determine the effectiveness of gene transfer and the effects of 
gene expression on tissues. Serum chemistries were measured 
before gene transfer and 17 days later to examine effects of 
D N A and DMRIE/DOPE liposomes on liver, renal, and cardiac 
function. 
The PCR reactions were performed as previously described 
(G.J. Nabel et al., 1993) with a 2-min annealing and extension 
at 72°C and 1 min of dissociation of 94°C. Plasmid D N A was 
used as positive control (1 ng). The sensitivity of detection has 
been estimated to be between 1 copy per 10^-10^ genomes 
(Stewart et al., 1929). Serum samples were stored frozen at 
-20°C for measurement of tissue-specific enzymes and routine 
biochemical parameters. 
Studies of cardiac toxicity 
The effects of intravenous DNA-liposome complexes on car-
diac tissue were assessed by measurement of total creatine 
phosphokinase (CPK), CPK isoenzymes, and electrocardi-
ography (EKG) on 15 mice prior to and following DNA-lipo-
some injection. Total C P K values were determined prior to 
injection. Mice received HLA-B7 DNA-liposome conjugates 
prepared as described above (0.1 cc) injected into the tail vein. 
C P K measurements were made on serum samples obtained 16 
hr after injection. Control mice were injected with 0.1 cc of 
saline, and total C P K was measured at 16 hr. 
As an independent parameter to evaluate cardiac function, 
E K G measurements were performed prior to DNA-liposome 
complex or saline injection, during injection, and I and 5 min 
following injection. The mice were anesthetized and surface 
lead electrodes were attached to the four limbs using alcohol. 
S A F E T Y A N D TOXICITY O F A N O V E L CATIONIC L I P O S O M E 783 
Surface lead I or II was monitored at a chart speed of 50 
mm/sec. After the baseline E K G was obtained, continuous 
measurements were made during injection. 
and standard errors of the mean (SEM) prior to and following 
gene transfer were compared using a two-tailed paired Mest. 
Results were considered statistically significant if p ̂  0.05. 
Direct arterial gene transfer in vivo 
Direct arterial transfection was performed in 12 pigs using 
methods as previously described in peripheral iliofemoral arter-
ies using a catheter (E.G. Nabel et al., 1990, 1992b). In this 
study, the expression ofthe human recombinant gene was ana-
lyzed up to 17 days following direct gene transfer in pigs. 
Genomic D N A was prepared from transfected and nontrans-
fected arteries, ovary or testes, heart, lung, liver, spleen, kid-
ney, and skeletal muscle by standard proteinase K digestion and 
phenol and chloroform extraction conditions. Oligonucleotide 
primers were synthesized to generate the 525-bp fragment as 
described above. 
Analysis of organ toxicity 
Organ specimens, including transfected and nontransfected 
artery, ovary or testes, brain, heart, lung, liver, spleen, kidney, 
and muscle were obtained when the animals were sacrificed, 
fixed in formalin, embedded in paraffin, and stained in hema-
toxylin and eosin. Representative sections were examined by an 
experienced pathologist (D.G.) in a blinded fashion. 
Serum from mice or pigs was obtained prior to sacrifice, 
frozen at — 20°C, and biochemical analyses were performed 
(Roche Biomedical Laboratories, Dublin, OH ) . Mean values 
RESULTS 
Comparison of transfection efficiencies of 
D M R I E I D O P E and DC-ChollDOPE in vitro 
To compare the efficacy of DMRIE/DOPE to the DC-Chol/ 
DOPE, a variety of cell lines were transfected in vitro. Among 
the cell lines, the DMRIE/DOPE formulation showed an im-
proved transfection efficiency ranging from two- to seven-fold, 
depending on the lines that were examined (Fig. 1). In general, 
the relative improvement with DMRIE/DOPE was most effec-
tive in cell lines that were difficult to transfect with both cat-
ionic lipids, e.g., M C A 205 fibrosarcoma. It is also important 
to note that a higher concentration of plasmid D N A was used 
with DMRIE/DOPE (5 jjig) than DC-Chol/DOPE (1 p,g) be-
cause this higher concentration of plasmid was toxic to cells in 
vitro with DC-Chol/DOPE (Stewart et al., 1992). Thus, 
DMRIE/DOPE is not necessarily more potent than DC-Chol/ 
DOPE, but its relative lack of toxicity allows larger quantities 
of D N A to be used in vitro and in vivo. 
In Fig. 2, an example is provided regarding the potential for 
improved therapy with this new liposome formulation. A sub-
clone of M C A 205, a murine fibrosarcoma (H-2K''), was poorly 
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FIG. 1. Improved transfection efficiency of DMRIE/DOPE DNA-liposome complex. Cells were incubated with DNA-lipo-
somes reconstituted in Ringer's lactate solution for 1.5 hr and analyzed after 36 hr. Transfection efficiencies of DMRIE/DOPE and 
DC-Chol/DOPE are shown. Percent transfected cells were analyzed by X-gal staining (Nabel et al., 1989). Standard deviations 
were < I 0 % . 




























FIG. 2. Improved antitumor effect with DMRIE/DOPE lipo-
somes compared to DC-Chol/DOPE. C57/BL6 mice (H-2K'') 
were inoculated with M C A 205 fibrosarcoma tumor cells sub-
cutaneously in the left posterior hind flank on day 0. Presensiti-
zation was performed by subcutaneous injection of BALB/c 
(H-2K'') spleen cells, 5 x 10* on day -6, and 2 x 10** on day 
-M. Tumors were injected (0.1 ml total volume) on days 15, 
18, and 20 with: (i) C M V H-2K'' 5 p-g and DMRIE/DOPE 15 
nmol (-•-); (ii) C M V H-2K'' 5 p-g and DMRIE/DOPE 15 nmol 
(-^-); and (iii) C M V H-2K'' 5 p.g and DC/Chol/DOPE 15 nmol 
(-•—). Tumor size, calculated as the product of two perpendic-
ular diameters, was measured at the indicated times. Standard 
deviations for each point were <20%. 
D O P E formulation, a marked antitumor effect was obtained 
after introduction of a foreign M H C gene (H-2K'') that was not 
seen with DC-Chol (Fig. 2). 
Distribution of DNA-liposome complexes after 
intravenous and intra-arterial administration 
To characterize the distribution of DNA-liposome com-
plexes after injection in vivo, the complexes were prepared and 
injected into the tail vein of BALB/c mice. The R S V HLA-B7 
plasmid used for the human gene therapy protocol was utilized 
for these studies. Increasing concentrations of DNA-liposome 
complexes were tested in three groups. The lowest dose repre-
sented a lO-fold higher initial dose than for the human gene 
therapy trial (0.5 p.g plasmid D N A ; 1.5 nmol DMRIE/DOPE) 
based on a weight/body surface area ratio. The highest dose was 
1,000-fold greater. PCR analysis of D N A from major murine 
organs, including heart, lung, brain, liver, and kidney, showed 
that the injected D N A was detected in multiple organs, includ-
ing the lung and heart, with these mice after 10 days (Table 
IA). However, the presence of D N A in these organs was not 
associated with organ pathology (see below). The localization 
of DNA-liposome complexes in different tissues has been de-
scribed previously (Stewart et al., 1992), where it was found 
transiently in cells ofthe reticuloendothelial cell system. 
Localized gene transfer to arterial segments was performed in 
12 pigs at three doses, HLA-B7 D N A 0.5 p,g and DMRIE/ 
D O P E 1.5 nmol (2 pigs), HLA-B7 D N A 5.0 p,g and DMRIE/ 
D O P E 15 nmol (4 pigs), and HLA-B7 D N A 50 p,g and DMRIE/ 
D O P E 150 nmol (6 pigs). The right and left iliofemoral arteries 
were transfected in the 12 pigs, for a total of 24 arteries. PCR 
analysis from these pigs demonstrated HLA-B7 D N A in 20 of 
24 arteries, 3 of 4 arteries transfected at the 0.5 p.g/1.5 nmol 
dose, 6 of 8 arteries transfected at the 5.0 p,g/15 nmol dose, and 
11 of 12 arteries transfected at the 50 p.g/150 nmol dose. In 
addition, P C R analysis did not demonstrate HLA-B7 D N A in 
major organs 17 days following intraarterial gene transfer (Ta-
ble IB). 
Table 1. Localization of Recombinant Genes by PCR after Introduction In Vivo in Mice and Pigs 
A. DNAiUposome 
0.5 p.g/1.5 nmol 
5.0 p-g/15 nmol 

















Mice were injected with 0.1 ml of the indicated concentradons of HLA-B7 
indicated dssues at 10 days for analysis by PCR. Mice received injections by tail 
total number analyzed is indicated. 
B. DNAiUposome 
0.5 p.g/1.5 nmol 
5.0 p.g/15 nmol 

































plasmid and DMRIE/DOPE, and D N A was extracted from the 


















Pigs were treated with indicated concentradons of plasmid D N A and DMRIE/DOPE by arterial gene transfer (Nabel et at., I993a,b). D N A was 
extracted from the indicated dssues at 17 days and analyzed as in A. 
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Table 2. Evaluation of Selected Serum Enzymes and Chemistries Before and After a Single Intravenous 




Alk Phos (lU/liter) 
Amylase (U/liter) 
Bilirubin (mg/dl) 
B U N (mg/dl) 
Creatinine (mg/dl) 
S G O T (lU/liter) 
Total protein (g/dl) 
Pre 
3.4 ± 0.4 
146 ± 21 




71 ± 8 





152 ± 13 
2,337 ± 192 
0.1 ±0 
25 ± 2 
0.6 ±0.3 
60 ± 7 
5.2 ±0.2 
Pre 
3.3 ± 0.4 
164 ± 14 
2,395 ± 277 
0.1 ±0 
35 ± 6 
0.5 ± 0.2 






170 ± 17 
2,465 ± 339 
O.I ±0 
26 ± 3 
0.3 ±0 




172 ± 8 
2,612 ± 166 
0.1 ±0.1 
24 ± 9 
1.0 ±0.2 






193 ± 23 
2,226 ±217 
0.1+0 
20 ± 0 
0.2 ± 0 
60 ± 8 
4.5 ±0.2 
Blood samples were obtained from BALB/c female mice (« = 5) prior to intravenous injection (Pre) and 10 days after (Post) tail vein injection 
with the indicated concentrations of DNA-liposome complexes. Serum enzyme and chemistry values were analyzed (Roche Biomedical Labora-
tory), and mean values and standard deviations are shown. 
Organ toxicity lymphoid aggregates in the lung or liver were seen in control 
animals that did not receive DNA-liposome treatments in pre-
To determine whether the introduction of DNA-liposome ^̂ ^̂ ^ ̂ ^̂ ^̂ ^ ̂ ^^ ^̂ ^̂ , ̂ , ̂ , j^^ja; Stewart et al., 1992). 
complexes in vivo produced toxicity to major organ systems, sî jî îŷ  „„ pathological abnonnalities were detected after 
several semm biochemical parameters were evaluated either ^̂ ^̂ ^ treatments with DNA-liposome complexes in mice (data 
after a single injection or after three separate injections made at ^̂ ^ ^j^^^^, analogous to the protocol used m our human clini-
2-week intervals in mice and pigs. The previous studies regard- ^̂ , ̂ .̂̂^ ̂ ^ j ^^^g, ̂, ̂^ ,992a, 1993). In addition, toxicity 
ing the long-term toxicity and immunologic consequences of ^̂ ^̂ .̂ ^ ̂ ^̂ ^ performed in pigs following direct arterial gene 
expression of a foreign M H C gene have been previously re- ^̂ ^̂ ^̂ ^̂  ̂^̂ ^̂ ^ pathology studies demonstrated that the admin-
ported with no adverse effects noted (E.G. Nabel etal.,\992a). .^^^^^^.^^ ̂^DNA-liposome complexes intra-arterially was well-
Analysis of serum enzymes and protein from liver, kidney, ĵ ĵ ^̂ ĵ j .̂  ̂ .̂ ^ ̂-̂ .̂  ̂ ^ ̂ ^̂ ^̂ ^̂  responses detected biochemi-
bone, and pancreas revealed no significant changes 10 days ^^„y (.j,̂,̂,̂  ̂ ^ ̂ ^ -^^ ̂j^^^^^ ^ j ^ ^ ^ ^ ĝ  
after a single injection (Table 2) or 14 days after three treat-
ments administered at 2-week intervals (Table 3). Similar anal-
yses were performed in pigs that received arterial gene transfer Cardiac toxicity 
with DNA-liposome complexes, and no biochemical abnor-
malities were observed (Table 4). Pathology analysis of tissues As in previous studies, plasmid D N A was detected after 
from these animals showed occasional incidental changes unre- intravenous injection in the heart by PCR analysis. Therefore, 
lated to the introduction of DNA-liposome complexes (Table we examined whether this formulation caused significant acute 
5). The incidental findings, including occasional peribronchial or chronic toxicity from this treatment. W e first evaluated the 
Table 3. Evaluation of Selected Serum Enzymes and Chemistries Before and After Three Intravenous 
Injections of HLA-B7 DNA-Liposome Complexes in Mice 
Plasmid ([Lg): 0.5 5 50 
DMRIEIDOPE (nmol): 1.5 15 150 
Pre Post Pre Post Pre Post 
Albumin (g/dl) 3.4 ± 0 2.9 ± 0 3.1 ±0.2 2.9 ± 0 3.2 ±0.1 3.2 ± 0.2 
Alk Phos (lU/liter) 152 ± 8 113 ± 1 0 161 ± 16 124 ± 14 170 ± 8 182 ± 1 1 
Amylase (U/liter) 2,246 ± 17 2,319 ± 185 2,213 ± 172 2,223 ± 116 2,585 ± 178 2,183 ± 277 
Bilimbin (mg/dl) 0.1 ± 0 0.1 ± 0 O . I ± 0 0.1 ± 0 0.1 ± 0 0.3 ± 0 
B U N (mg/dl) 21 ± 3 18 ± 3 37 ± 7 23 ± 8 26 ± 10 22 ± 3 
Creatinine (mg/dl) 0.7 ± 0 0.4 ± 0.3 0.4 ± 0.3 0.4 ±0.3 1 ± 0 0.3 ± 0 
Phosphorous (mg/dl) 6.7 ± 0.5 6.2 ± 0.5 7.2 ± 0.5 5 ± 0.8 7.6 ± 0.9 7.7 ±1.8 
S G O T (lU/liter) 69 ± 1 0 53 ± 15 56 ± 3 69 ± 28 41 ± 13 46 ± 2 
SGPT (lU/liter) 35 ± 3 27 ± 9 31 ± 8 37 ± 5 25 ± 4 26 ± 2 
Total protein (g/dl) 6.3 ± 1 4.8 ± 0.3 5.4 ± 0.9 5.1 ±0.5 5.0 ± 0 4.8 ± 0 
Blood samples were obtained from BALB/c female mice (« = 5) prior to intravenous injection (Pre) and 14 days after (Post) the third injection of 
DNA-liposome complexes at the indicated concentrations. Serum enzyme and chemistry values were analyzed (Roche Biomedical Laboratory), 
and mean values and standard deviations are shown. 
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Table 4. Evaluation of Selected Serum Enzymes and Chemistries Before and After Arterial Gene Transfer 




Alk Phos (lU/liter) 
Amylase (U/liter) 
Bilimbin (mg/dl) 





L D H (lU/liter) 
Phosphorous (mg/dl) 
Potassium (mEq/liter) 
S G O T (lU/liter) 
SGPT (lU/liter) 
Sodium (mEq/liter) 





298 ± 62 




101 ± 1 
0.9 ±0.1 
111 ±57 
538 ± 146 
10.3 ±0.7 
5.1 ± 1.0 
28 ±8 
29 ± 14 




186 ± 29 
2,170 ±470 
0.22 ± 0.04 




134 ± 54 
507 ± 161 
7.9 ±0.8 
4.4 ± 0.8 
44 ± 30 
42 ± 12 






































3.4 ± 0.3 
206 ± 51 
2,527 ± 1,297 
0.14 ±0.05 
10 ±2 
9.5 ± 1.0 
101 ± 5 
1.2 ±0.2 
116 ±22 
489 ± 173 
10.9 ±4.1 
4.8 ± I.l 
43 ± 30 
40 ± 7 
142 ±9 
5.7 ±0.5 
Blood samples were obtained from pigs (n = 10) prior to (Pre) and 17 days after (Post) arterial gene transfer of DNA-liposome complexes at the 
indicated concentrations (n = 5 for each concentration). Serum enzyme and chemistry values were analyzed (Roche Biomedical Laboratory), and 
mean values and standard errors of the mean are shown. All values fall within the range of normal limits (Nabel et al., 1992a). 
potential for acute effects of this treatment by examining the 
electrocardiogram before, during, and after injection on 
DMRIE/DOPE plasmid complexes. As observed with DC-Chol 
liposomes, this analysis revealed no abnormalities in rate or 
rhythm after intravenous injection (Fig. 3). As a further evalua-
tion of cardiac toxicity, CPK measurements were perfonned in 
mice before or after injection with DNA-liposome complexes. 
No significant changes in CPK levels were noted pre- or post-
injection (Table 6). In addition to these analyses, histopatholog-
ical analysis of tissue was performed. No significant pathologi-
cal abnormalities were detected at 14 days to 6 weeks after 
injection (Table 5). In summary, despite the detection of com-
plexes by PCR within the myocardium, there was no acute or 
chronic cardiac toxicity from this treatment. 
DISCUSSION 
The potential of nonviral vectors as a delivery vehicle for 
human gene therapy has expanded over the past several years. 
Table 5. Histological Analysis of Tissue Following Introduction of DNA-Liposomes In Vivo 
Species: 



































































ND, not determined. 
"Minor pathologic changes of no clinical significance. 
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FIG. 3. Effect of DNA-liposome infusions on cardiac rate and rhythm measured by electrocardiography. Five mice were 
monitored electrocardiographically before and after intravenous infusions of saline (control, « = 2) or HLA-B7 liposomes (n = 3). 
Female BALB/c mice were anesthetized by metathane inhalation. Surface electrodes were attached to the four limbs, and surface 
lead I or II was recorded continuously at 50 mm/sec paper speed. Representative tracings are shown for each group pre-injection 
and 5 min post-injection. 
In theory, a variety of such vectors could be employed for gene 
transfer in vivo, including DNA-liposome complexes, naked 
plasmid D N A , protein/DNA, or inactivated viral D N A com-
plexes. In this study, we examine the toxicities of a novel 
DNA-liposome complex that may provide for a substantial 
increase in the amount of recombinant D N A which could be 
administered in vivo. In this formulation, the cationic lipid, 
DMRIE, has been substituted for DC-Chol. The resulting 
DNA-liposome complex has enhanced transfection efficiencies 
in vitro (Fig. 1). Although the magnitude of this effect is rela-
tively small (two- to seven-fold), these plasmids do not aggre-
gate at higher cell concentrations, and a substantially higher 
quantity of plasmid can be introduced in vivo by this method. 
This DNA-liposome also has the ability to facilitate an antitu-
mor response in a case where the other liposome is less active 
(Fig. 2). 
The ability to introduce genes at higher concentrations could 
enhance gene transfer and stimulate increased synthesis of gene 
products that are required for therapeutic effects. For example, 
recently, high-level concentrations of Lipofectin (BRL, Gaith-
ersburg, M D ) and plasmid expression vectors have been de-
scribed that allow for gene expression systemically following 
intravenous infection (Zhu et al., 1993). Additional Phase I 
studies will be required in humans to test this possibility. This 
Table 6. Measurements of Total CPK (U/L) 
Before and After Intravenous Injection 







339 ± 122 
189 ± 63 
p « 0.79 
5 
15 
156 ± 44 
163 ± 44 
p « 0.96 
50 
150 
156 ± 44 
163 ± 44 
p^0.3l 
Serum samples were obtained from BALB/c female mice prior to 
intravenous injection and 16 hr following injecdon of HLA-B7 lipo-
some complexes (n = 5, each dose). Serum was analyzed by Roche 
Biomedical Laboratory (Buriington, NC). 
study, together with previous studies that have demonstrated 
the relative safety of other DNA-liposome complexes (Nabel et 
al., 1992a; Stewart et al., 1992), provides evidence that the 
administration of such compounds in vivo is well tolerated. 
The present study confirms that this treatment is tolerated at 
doses up to 1,000-fold higher than previously analyzed and has 
the potential to deliver larger quantities of genes. As in previous 
studies, although D N A was detected in the myocardium follow-
ing intravenous injection, there was no effect on myocardial 
function, either acutely or chronically. Therefore, the intrave-
nous infusion of DNA-liposome complexes continues to appear 
safe with regard to cardiac function even at higher doses. Fi-
nally, the concern was raised regarding the potential for inad-
vertent introduction of D N A into germ cells. W e found that 
D N A was not detected in gonadal tissue, following gene trans-
fer with DNA/DC-Chol complexes, even by PCR (Nabel etal., 
1992a). The previous study used lower doses of the D N A -
liposome complex. The present study also confirms that the 
lack of recombinant D N A in gonadal tissue at concentrations up 
to 1,000-fold greater than those reported previously. Taken 
together, these data suggest that several cationic lipids may be 
useful for human gene therapy and are unlikely to cause signif-
icant toxicity at these doses, even when modifications are made 
in one ofthe charged lipid components. These data also suggest 
that additional modifications of the lipid can be incorporated in 
the future that will facilitate the efficiency of targeting D N A -
liposome complexes to specific tissues in vivo. 
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